Lamotrigine Tablet, Extended Release
Product Images NDC 55111-428
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 55111-428). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Dr.reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Container2 (Container2)
Container3 (Container3)
Container4 (Container4)
Container5
Lamotrigine Extended-Release Tablets USP 250 mg is a medication prescribed for the treatment of seizures in patients suffering from epilepsy. This medication comes in a tablet form, and each tablet contains 250 mg of the active ingredient. The extended-release tablets are designed to release the medication slowly in the body, which helps to maintain a steady level of medicine in the blood and reduces the risk of side effects. Note that the text contains some errors and non-English characters.*
Container6 (Container6)
Figure1 (Figure1)
This appears to be a graph depicting the responder rates, improvement, and worsening of patients taking placebo and Lametrigine ER Tablets. The percentages displayed on the Y-axis range from -100% to 75%, while the X-axis shows the different categories of responders, improved patients, and worsened patients. The numbers in the graph represent the percentage of patients falling under each category.*
Figure2 (Figure2)
Pictures (Pictures)
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.